Rocket Pharmaceuticals
RCKT
164 hedge funds and large institutions have $1.52B invested in Rocket Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 17 closing their positions.
341% more call options, than puts
Call options by funds: $4.54M | Put options by funds: $1.03M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13% more capital invested
Capital invested by funds: $1.34B → $1.52B (+$177M)
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
1% more funds holding
Funds holding: 163 → 164 (+1)
3.73% less ownership
Funds ownership: 98.63% → 94.9% (-3.7%)
Top Buyers
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$17M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.1M |
| 4 |
BlackRock
New York
|
-$6.69M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$5.59M |
RCKT Hedge Fund Activity: Q2 2023 in Review
164 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2023, worth a combined $1.52B — up 13% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RCKT positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $20.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.4M sold.
- 164 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2023, up from 163 in Q1 2023.
- Funds reported $1.52B of Rocket Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
- 18 funds opened new Rocket Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals buyer in Q2 2023 was Wellington Management Group, an estimated $20.9M added.
- The largest Rocket Pharmaceuticals seller in Q2 2023 was RA Capital Management, an estimated $19.4M sold.
Based on aggregated 13F filings for Q2 2023.